AxoGen, Inc. (AXGN)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$48.28+2.51%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Research Workspace
Put AXGN beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (3q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Maintain gross margin between 74% and 76% in 2026: FY26 GM guidance 73.0% vs 74-76% target; Q2 actual 72.7%.
View ThesisRevenue growth is accelerating — up about 24% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on margins.
View ManagementExpectations look high — the market is pricing in about 45% growth a year, above the roughly 23% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 2% a day.
View RiskAxoGen's growth has to keep compounding to justify the price. Revenue grew 23% year over year, and the last quarter beat expectations. It trades at 10× price-to-sales versus a 2.9× peer median, indicating the market is pricing in more growth than forecast. The primary risk is maintaining gross margin between 74% and 76% in 2026, as it currently stands at 72.7%. Peer multiples imply a price about 46% below where it trades (it looks expensive on this basis). This read is provisional.
Trailing returns as of 2026-09-04. AXGN is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 10 analysts currently covering AXGN (as of Sep 2026).
Based on 3 Wall Street analysts offering 12-month price targets for AXGN in the last 4 months.
Continue this research
Compare AXGN with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| AXGN Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 4 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put AXGN next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $48.28
The last 12 months of price, then the range of analyst 12-month targets from today’s $48.28.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.